Novartis Pharma AG: Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

AI Briefing

• – Novartis presents new data on early symptom relief and long-term control in complex skin diseases, including chronic spontaneous urticaria, at the AAD 2026 conference.
• – Studies show symptom control as early as week 1 with Rhapsido REMIX-1 & -2 pooled analysis.
• – Long-term Cosentyx data builds on extensive body of evidence supporting its effectiveness in treating complex skin diseases.